The 19th edition of the International Congress on Targeted Anticancer Therapies (TAT) will take place in Paris, France, 1-3 March 2021.
The development of novel anticancer agents in hypothesis-testing trials can transform our understanding of malignancies and impact clinical care. The TAT meeting is a meeting focused on early clinical trials and has been described as ‘The home of phase I in oncology’. This meeting will be entirely dedicated to improving the conduct of early anti-cancer clinical trials, with presentations, discussions and educational reviews and workshops highlighting emerging pre-clinical and clinical data, as well as defining optimal methodologies for early clinical trials. Our vision is to facilitate and accelerate the early development of novel anticancer drugs. We believe that with many new therapies entering clinical testing, high quality, customized, well designed phase I studies questioning key hypotheses and providing robust answers to these questions are critically important and will be the platform upon which therapeutics will succeed or fail.
The TAT 2021 Congress will bring together experts in anticancer drug discovery and clinical development, translational scientists, and regulators in a unique forum to highlight recent advances and new data, whilst promoting collaboration and knowledge-sharing in a bench-to-bedside approach. In addition, there are opportunities for new investigators and faculty to present their work and interact with experts, and mentoring opportunities through workshops.
In Keynote lectures, Educational sessions, Workshops, Scientific Sessions and Poster exhibition based on abstracts selection, attendees will be able to update their knowledge on:
- Drug discovery and development for a broad range of targets
- Pre-clinical testing to identify effective combination strategies
- Immune based therapies including ADCs, cytokines, multitargeted agents and cell-based therapies
- The microbiome as a tool and a target
- Oncolytic viruses
- Incorporating genomics into early drug development
- Precision medicine including practical aspects of optimising molecular tumour boards for phase I trials
- Early clinical trial methodology including design, conduct and endpoints
ESMO-MORA: The TAT 2021 programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
The congress webcasts will include all the sessions of the official programme, where speaker permission is granted, and will be available on this website and on OncologyPRO for ESMO members.